腎臓がんおよび腎細胞がん薬の世界市場-2023年～2030年

市場概要

腎臓がんおよび腎細胞がん薬の世界市場は、2022年に56億米ドルに達し、2030年には89億米ドルに達することで有利な成長が予測されています。世界の腎臓がんおよび腎細胞がん薬市場は、予測期間中（2023～2030年）に6.3%のCAGRを示すと予測されています。

新規薬剤や腎臓がん治療戦略の開発は、製薬企業や研究機関から多額の資金提供を受けています。このような継続的な研究開発活動により、さらに最先端の強力な薬剤が市場に導入され、将来の拡大に拍車がかかると予想されます。

市場力学

活発な主要企業が、予測期間中の世界の腎臓がんおよび腎細胞がん薬市場の成長を後押ししています

2022年10月、腎臓がん治療薬FotivdaのFDA承認取得を目前にして、Aveo Oncology社は転換を図っています。LG化学は現在、アヴェオによるLG化学の買収により、Fotivdaとアヴェオの他のがん候補薬の開発をより成功させるつもりです。アヴェオは、3月に再発または抵抗性の進行腎細胞がんのサードライン治療薬としてFDAから予想外の承認を受けたフォティブダの他に、3つのがん候補を有しています。

アヴェオは最近、2028年に期限切れとなるフォティブダの特許を2039年まで延長できることを発見し、LG化学にとってより望ましいものとなっています。

個別化医療の開拓が腎臓がんおよび腎細胞がん薬市場に成長機会をもたらす

腎臓がんの遺伝的・分子的側面に対する理解が深まった結果、個別化医療技術が生み出されました。オーダーメイドの治療計画を立てるために、遺伝子検査やバイオマーカー分析が腫瘍の特定の変異や異常の検出に役立っています。特定の遺伝的欠陥をターゲットとする薬剤は、個別化治療に焦点が当てられているため需要が高く、市場拡大を後押ししています。

腎臓がんやRCCに関与する特定の分子標的に特異的に取り組む標的薬は、個別化医療によって可能になっています。免疫チェックポイント阻害剤やチロシンキナーゼ阻害剤（TKI）などのこれらの医薬品は、腫瘍の発生や生存に不可欠な特定の分子や経路をブロックするように作られています。

COVID-19の影響分析

COVID-19の大流行は腎臓がんおよび腎細胞がん薬市場に大きな影響を与えました。パンデミックは世界の物流とサプライチェーンに影響を及ぼし、特に腎臓がんと腎細胞がんの治療に必要な薬剤の入手に支障をきたしました。重要な医薬品の安定供給を維持する努力にもかかわらず、時折、不足が生じたり、配送が遅れたりしています。さらに、国境の閉鎖や輸送の制限によって医薬品の輸出入が妨げられ、地域によってはアクセスが妨げられている可能性もあります。

2023年現在、COVID-19の状況は回復しており、すべての患者がヘルスケア施設にアクセスできるようになり、腎臓がんおよび腎細胞がん薬の需要が増加しています。

ロシア・ウクライナ紛争分析

ロシア・ウクライナ紛争が腎臓がんおよび腎細胞がん薬市場に与える影響は複雑かつ多面的です。紛争はヘルスケアシステムに負担をかける可能性があり、がん治療のような専門的治療からリソースと焦点を奪う。最良の治療を提供するためには、病院やヘルスケア施設にとって、特殊な薬剤へのアクセスなどの問題が生じる可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 腎臓がんおよびRCC患者の増加
  • 抑制要因
    • これらの薬剤に伴う副作用
  • 機会
    • 研究開発
  • 影響分析

第5章 産業分析

• ポーターの5フォース分析
• サプライチェーン分析
• アンメットニーズ
• 規制分析

第6章 COVID-19分析

第7章 ロシア・ウクライナ戦争分析

第8章 人工知能分析

第9章 製品別

• ベバシズマブ
• エベロリムス
• カボザンチニブ
• アキシチニブ
• ソラフェニブ
• テムシロリムス
• スニチニブ
• パゾパニブ

第10章 エンドユーザー別

• 病院
• 外来手術センター
• 専門クリニック
• その他

第11章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第12章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ

第13章 競合情勢

• 競合シナリオ
• 製品ベンチマーク
• 企業シェア分析
• 主な発展と戦略

第14章 企業プロファイル

• Roche Inc
  • 企業概要
  • 製品ポートフォリオと概要
  • 財務概要
  • 主な発展
• GlaxoSmithKline Plc.
• Active Biotech Ab
• Heidelberg Pharma AG, Inc.
• Bristol-Myers Squibb
• Eisai
• Exelixis.,
• Novartis AG
• Amgen
• Bayer AG

第15章 付録

Market Overview

The Global Kidney Cancer and Renal Cell Carcinoma Drugs Market reached US$ 5.6 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 8.9 billion by 2030. The global kidney cancer and renal cell carcinoma drugs market is expected to exhibit a CAGR of 6.3% during the forecast period (2023-2030).

The development of novel medications and kidney cancer treatment strategies is receiving significant funding from pharmaceutical corporations and research organizations. The introduction of additional cutting-edge and potent medications to the market is anticipated to result from this ongoing research and development activity, spurring future expansion.

Market Dynamics

Active Major Players Are Boosting The Global Kidney Cancer And Renal Cell Carcinoma Drugs Market Growth During The Forecast Period.

In October 2022, on the approach to receiving FDA approval for its kidney cancer medication Fotivda, Aveo Oncology took a diversion. LG Chem now intends to have better success developing Fotivda and Aveo's other cancer candidates due to Aveo's acquisition of LG Chem. Aveo has three other cancer candidates in addition to Fotivda, which was unexpectedly approved by the FDA in March for the third-line treatment of advanced renal cell carcinoma that has relapsed or is resistant.

Aveo recently found that its patent on Fotivda, set to expire in 2028, could really be extended all the way to 2039, making it more desirable for LG Chem.

The Development Of Personalized Medicines Provides Kidney Cancer And Renal Cell Carcinoma Drug Market Growth Opportunities.

Personalized medicine techniques have been created as a result of our growing understanding of the genetic and molecular aspects of kidney cancer. In order to develop customized treatment plans, genetic testing, and biomarker analyses help detect certain mutations or abnormalities in tumors. Drugs that target particular genetic defects are in high demand due to the focus on personalized therapy, which is propelling market expansion.

Targeted medicines that specifically tackle particular molecular targets involved in kidney cancer and RCC have been made possible by personalized medicine. These medications, such as immune checkpoint inhibitors and tyrosine kinase inhibitors (TKIs), are made to block particular molecules or pathways that are essential for the development and survival of tumors.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the kidney cancer and renal cell carcinoma drugs market. The pandemic has impacted worldwide logistics and supply chains, which has caused disruptions in the accessibility of drugs, especially those required to treat kidney cancer and RCC. Despite efforts to keep a consistent supply of important pharmaceuticals, there have occasionally been shortages and delays in their delivery. Additionally, border closures and limits on transportation may have hindered the import and export of pharmaceuticals, which could have hampered access in some regions.

As of 2023, the COVID-19 situation is recovering and all patients can access the healthcare facilities leading to increasing demand for kidney cancer and renal cell carcinoma drugs.

Russia-Ukraine Conflict Analysis

The impact of the Russia-Ukraine war on the kidney cancer and renal cell carcinoma drugs market is complex and multifaceted. The dispute may put a strain on the healthcare system, taking resources and focus away from specialized treatments like cancer therapy. Providing the best care may present issues for hospitals and healthcare facilities, including access to specialized medications.

Segment Analysis

The global kidney cancer and renal cell carcinoma drugs market is segmented based on product, end-user, distribution channel, and region.

The Everolimus Segment Is Expected To Hold A Position In The Market Over The Forecast Period.

The Everolimus segment accounted for one of the highest market stake accounting for approximately 22.3% of the kidney cancer and renal cell carcinoma drugs market in 2022. Everolimus works by inhibiting the mTOR pathway, which is involved in regulating cell growth, proliferation, and angiogenesis (the formation of new blood vessels). By inhibiting mTOR, Everolimus helps slow down the growth of cancer cells and prevents the formation of new blood vessels that supply nutrients to the tumor. Everolimus can be used as a single agent or in combination with other drugs for the treatment of advanced RCC.

Geographical Analysis

An Increasing Number Of Patients With Kidney Cancer, FDA Approvals, And Advancement In Kidney Cancer And Renal Cell Carcinoma Drugs Dominate The European Region.

Europe is expected to dominate the kidney cancer and renal cell carcinoma drugs market, accounting for around 27.9% of this market. Different European nations have different rates of kidney cancer, particularly renal cell carcinoma (RCC). With more than 115,000 cases identified each year and 49,000 fatalities, kidney cancer is the fifth most prevalent malignancy in Europe.

In Europe, there are more people over the age of 65 than anywhere else in the world. The incidence of kidney cancer tends to rise with age, and the aging population adds to the disease's overall prevalence.

Competitive Landscape

The major global players in the market include: Roche Inc, GlaxoSmithKline Plc., Active Biotech Ab., Heidelberg Pharma AG, Inc., Bristol-Myers Squibb, Eisai, Exelixis, Novartis AG, Amgen, and Bayer AG among others.

Why Purchase the Report?

• To visualize the global kidney cancer and renal cell carcinoma drugs market segmentation based on the product, end-users, distribution channel, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous kidney cancer and renal cell carcinoma drugs market-level data points with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global kidney cancer and renal cell carcinoma drugs market report would provide approximately 61 tables, 63 figures, and 195 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product
• 3.2. Snippet by End-users
• 3.3. Snippet by Distribution Channel
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Growing incidences of kidney and RCC cases
  • 4.1.2. Restraints
    • 4.1.2.1. Side effects associated with These Drugs
  • 4.1.3. Opportunity
    • 4.1.3.1. Research and development
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Unmet Needs
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers' Strategic Initiatives
• 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Artificial Intelligence Analysis

9. By Product

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 9.1.2. Market Attractiveness Index, By Product
• 9.2. Bevacizumab*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Everolimus
• 9.4. Cabozantinib
• 9.5. Axitinib
• 9.6. Sorafenib
• 9.7. Temsirolimus
• 9.8. Sunitinib
• 9.9. Pazopanib

10. By End-users

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
  • 10.1.2. Market Attractiveness Index, By End-users
• 10.2. Hospitals*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Ambulatory Surgical Centers
• 10.4. Specialty Clinics
• 10.5. Others

11. By Distribution Channel

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.1.2. Market Attractiveness Index, By Distribution Channel
• 11.2. Hospital Pharmacies*
  • 11.2.1. Introduction
  • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 11.3. Retail Pharmacies
• 11.4. Online Pharmacies

12. By Region

• 12.1. Introduction
  • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 12.1.2. Market Attractiveness Index, By Region
• 12.2. North America
  • 12.2.1. Introduction
  • 12.2.2. Key Region-Specific Dynamics
  • 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
  • 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.2.6.1. The U.S.
    • 12.2.6.2. Canada
    • 12.2.6.3. Mexico
• 12.3. Europe
  • 12.3.1. Introduction
  • 12.3.2. Key Region-Specific Dynamics
  • 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
  • 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.3.6.1. Germany
    • 12.3.6.2. The U.K.
    • 12.3.6.3. France
    • 12.3.6.4. Italy
    • 12.3.6.5. Spain
    • 12.3.6.6. Rest of Europe
• 12.4. South America
  • 12.4.1. Introduction
  • 12.4.2. Key Region-Specific Dynamics
  • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
  • 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.4.6.1. Brazil
    • 12.4.6.2. Argentina
    • 12.4.6.3. Rest of South America
• 12.5. Asia-Pacific
  • 12.5.1. Introduction
  • 12.5.2. Key Region-Specific Dynamics
  • 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
  • 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.5.6.1. China
    • 12.5.6.2. India
    • 12.5.6.3. Japan
    • 12.5.6.4. Australia
    • 12.5.6.5. Rest of Asia-Pacific
• 12.6. Middle East and Africa
  • 12.6.1. Introduction
  • 12.6.2. Key Region-Specific Dynamics
  • 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
  • 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

13. Competitive Landscape

• 13.1. Competitive Scenario
• 13.2. Product Benchmarking
• 13.3. Company Share Analysis
• 13.4. Key Developments and Strategies

14. Company Profiles

• 14.1. Roche Inc*
  • 14.1.1. Company Overview
  • 14.1.2. Product Portfolio and Description
  • 14.1.3. Financial Overview
  • 14.1.4. Key Developments
• 14.2. GlaxoSmithKline Plc.
• 14.3. Active Biotech Ab
• 14.4. Heidelberg Pharma AG, Inc.
• 14.5. Bristol-Myers Squibb
• 14.6. Eisai
• 14.7. Exelixis.,
• 14.8. Novartis AG
• 14.9. Amgen
• 14.10. Bayer AG

LIST NOT EXHAUSTIVE

15. Appendix

• 15.1. About Us and Services
• 15.2. Contact Us